 |
|
Johns Hopkins scientists discover what drives the development of a fatal form of malaria
August 19, 2008The culprit: one's own immune system
Platelets - those tiny, unassuming cells that cause blood to clot and scabs to form when you cut yourself - play an important early role in promoting cerebral malaria, an often lethal complication that occurs mostly in children. Affecting as many as half a billion people in tropical and subtropical regions, malaria is one of the oldest recorded diseases and the parasite responsible for it, Plasmodium, among the most studied pathogens of all time. Still, cerebral malaria, which results from a combination of blood vessel and immune system dysfunction, is not well understood.
In a study described in the August 14 issue of Cell Host and Microbe, Johns Hopkins researchers reveal that when red blood cells are infected with the malaria parasite, they activate platelets to secrete the PF4 protein, which triggers the immune system to inflame blood vessels and obstruct capillaries in the brain; both are hallmarks of cerebral malaria.
In their experiments, the Hopkins team first infected human red blood cells in culture with the malaria parasite and found that this did, indeed, induce platelet activation.
The researchers then infected separate sets of live mice with the malaria parasite: one set treated so that it lacked platelets altogether and two others treated with aspirin or Plavix, platelet inhibitors that prevent the release of PF4.
The survival rate of mice without platelets as well as those treated with inhibitors was improved over that of the mice left alone, but only when the treatment began very soon after infection. When researchers started treating mice with platelet inhibitors one day after infecting them, those mice survived more often than control mice. However, when researchers waited until after three days to treat infected mice with platelet inhibitors, that group did no better in terms of survival.
"Cerebral malaria is lethal 20 percent of the time in the best of hands, and here we've shown that something as simple as aspirin, because of its affect on platelets, might be able to improve the outcomes of those who contract this deadly form of the disease," says David Sullivan M.D., an associate professor of molecular microbiology and immunology in the Johns Hopkins University Bloomberg School of Public Health.
To make the specific connection between PF4 and malaria, the scientists compared the responses to malaria infection by so-called "wild type" normal mice and mice genetically engineered to lack pF4. They found that the amount of parasite in the blood was the same in both sets of mice. The notable difference was in the animals' immune responses to that same parasite burden. More than 60 percent of the mice lacking PF4 were still alive after day 10, while only 30 percent of the mice with PF4 survived that long.
"The take-home lesson is that platelets, by releasing PF4, are playing an early role in the wind-up phase of cerebral malaria," says Craig Morrell, DVM, Ph.D., an assistant professor of molecular and comparative pathobiology at the Johns Hopkins University School of Medicine. "Our mouse studies show that timing is critical; with the mice, we know when we infected them and controlled when we treated them. A big challenge in translating this to humans is that people don't know when they get infected.
"Platelets don't get any respect, but they're the second most abundant cell in the blood after red blood cells and packed full of factors that rally the immune system to action. By taking what we know about platelets and their activation and applying it to malaria, we have found a driver of cerebral malaria."
Johns Hopkins Medical Institutions
In their experiments, the Hopkins team first infected human red blood cells in culture with the malaria parasite and found that this did, indeed, induce platelet activation.
The researchers then infected separate sets of live mice with the malaria parasite: one set treated so that it lacked platelets altogether and two others treated with aspirin or Plavix, platelet inhibitors that prevent the release of PF4.
The survival rate of mice without platelets as well as those treated with inhibitors was improved over that of the mice left alone, but only when the treatment began very soon after infection. When researchers started treating mice with platelet inhibitors one day after infecting them, those mice survived more often than control mice. However, when researchers waited until after three days to treat infected mice with platelet inhibitors, that group did no better in terms of survival.
"Cerebral malaria is lethal 20 percent of the time in the best of hands, and here we've shown that something as simple as aspirin, because of its affect on platelets, might be able to improve the outcomes of those who contract this deadly form of the disease," says David Sullivan M.D., an associate professor of molecular microbiology and immunology in the Johns Hopkins University Bloomberg School of Public Health.
To make the specific connection between PF4 and malaria, the scientists compared the responses to malaria infection by so-called "wild type" normal mice and mice genetically engineered to lack pF4. They found that the amount of parasite in the blood was the same in both sets of mice. The notable difference was in the animals' immune responses to that same parasite burden. More than 60 percent of the mice lacking PF4 were still alive after day 10, while only 30 percent of the mice with PF4 survived that long.
"The take-home lesson is that platelets, by releasing PF4, are playing an early role in the wind-up phase of cerebral malaria," says Craig Morrell, DVM, Ph.D., an assistant professor of molecular and comparative pathobiology at the Johns Hopkins University School of Medicine. "Our mouse studies show that timing is critical; with the mice, we know when we infected them and controlled when we treated them. A big challenge in translating this to humans is that people don't know when they get infected.
"Platelets don't get any respect, but they're the second most abundant cell in the blood after red blood cells and packed full of factors that rally the immune system to action. By taking what we know about platelets and their activation and applying it to malaria, we have found a driver of cerebral malaria."
Johns Hopkins Medical Institutions
Cerebral Malaria Current Events and Cerebral Malaria News RSSU of M researchers find cerebral malaria may be a major cause of brain injury in African children
Researchers at the University of Minnesota have found that cerebral malaria is related to long-term cognitive impairment in one of four child survivors. The research is published in the current issue of the journal Pediatrics.
MSU researcher helps develop computer game for Ugandan children recovering from cerebral malaria
The computer program Captain's Log - originally used with individuals diagnosed with attention deficit hyperactivity disorder, brain injuries or learning disabilities - is being adapted to rehabilitate Ugandan children who are survivors of cerebral malaria.
Cerebral malaria: Approaching a diagnostic test
Scientists at CNRS and the Pasteur Institute, collaborating with physicians in Gabon, have just undertaken a study on cerebral malaria in children living in an endemic region.
Eye-opening research provides important diagnostic tool for major childhood killer
The eye can provide a very reliable way of diagnosing cerebral malaria, researchers in Malawi have shown.
Possible new compound for treatment of cerebral malaria
In a paper published online in PLoS Medicine researchers from Marseille describe the effects of a new compound that may be a future treatment for patients with cerebral malaria.
Brain Wave Monitor Could Replace Lumbar Puncture
Scientists in Southampton have developed non-invasive technology to measure the fluid pressure in the brain safely and painlessly which they hope will eventually reduce the need for a lumbar puncture. Collaborators in London now believe it could be a major advance in the diagnosis and treatment of conditions such as meningitis, head injury and sleeping disorders. It could even be used by astronauts in space.
Malaria : Plasmodium togetherness a strategy for breeding success
Malaria, which infects 600 million people in the world and leads annually to 2 million deaths, is the most widespread of infectious diseases. The pathological agent is a microscopic parasite of the Plasmodium genus which develops inside the host's erythrocytes. Plasmodia go through a series of asexual reproduction cycles before a transition takes place from asexual stages to production of sexual cells, the gametocytes or pre-gametes, in the host blood. The females of Anopheles, the mosquito vector, ingest blood and gametocytes during a nocturnal feed on human skin. The meal reaches the mosquito's stomach where Plasmodium sexual reproduction takes place. An encounter and subsequent binding be
More Cerebral Malaria Current Events and Cerebral Malaria News Articles
 | Immunology and Immunopathogenesis of Malaria (Current Topics in Microbiology and Immunology) Malaria is still a major global health problem, killing more than 1 million people every year. Almost all of these deaths are caused by Plasmodium falciparum, one of the four species of malaria parasites infecting humans. This high burden of mortality falls heavily on Sub-Saharan Africa, where over 90% of these deaths are thought to occur, and 5% of children die before the age of 5 years. The... |
| Fibrin-degradation products in cerebral malaria by H. A Reid | |
| Use of dexamethasone in cerebral malaria by A. W Woodruff | |
| Standards for adjudicating claims presented by veterans suffering from hepatitis C, cerebral malaria, and Persian Gulf illnesses: Hearing before the Subcommittee ... Congress, second session, July 16, 1998 by United States |
| © 2008 BrightSurf.com |